Strategic partnerships Neuraly actively collaborates with external entities, evidenced by the Enigma Biomedical partnership to deploy its PET imaging tracer PMI04, signaling openness to co-development and tech-sharing deals that can be leveraged for joint ventures and licensing.

Neurodegenerative focus With a clinical-stage portfolio targeting Parkinson’s, Alzheimer’s, and other neurodegenerative diseases, Neuraly presents opportunities for late-stage trial support, biomarker validation services, and access to specialized CNS contract research or manufacturing capabilities.

Imaging and biomarkers The involvement in PET imaging tracers for microglia activity positions Neuraly as a potential customer or partner for imaging reagent supply, imaging services, and companion diagnostic development in neurology programs.

Financing signals Historical Series A funding and a current revenue range imply a growth-oriented but lean capacity profile, suggesting opportunities for pilot-scale collaborations, staged collaborations, or service-based engagements that align with funding timelines.

Regional focus Located in Gaithersburg, Maryland with a small to mid-size employee base, Neuraly may benefit from regional CRO/CMO partnerships, regulatory consulting, and localized manufacturing or logistics support to accelerate development timelines.